MONORES ® - Clenbuterol

MONORES ® is a drug based on Clenbuterol hydrochloride

THERAPEUTIC GROUP: Adrenergics for aerosols and other drugs for obstructive syndromes of the respiratory tract.

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications MONORES ® - Clenbuterol

MONORES ® is indicated for the treatment of bronchial asthma and chronic obstructive pulmonary disease characterized by asthma.

Mechanism of action MONORES ® - Clenbuterol

MONORES ® is a specialty based on Clenbuterol, an active ingredient listed among the selective beta 2 adrenergic receptor agonists.

To the openness of the other sympathomimetic amines with selectivity towards the aforementioned receptors also in Clenbuterol it binds with high affinity the Beta 2 adrenergic receptors expressed by the smooth tracheobronchial musculature, determining a significant bronchodilation important in restoring the correct patency of the respiratory tract.

The concurrent fluidifying action on the nasal mucus secretions, makes the mucus significantly more fluid, thus facilitating its elimination through mucous-ciliary clearance, and further improving the patient's ventilatory capacity.

Following the administration of MONORES ®, the amount of Clenbuterol absorbed is subsequently eliminated via the kidneys.

Studies carried out and clinical efficacy

IMMUNOLOGICAL EFFECTS OF CLENBUTEROL

J Pharmacol Sci. 2007 Jun; 104 (2): 146-52. Epub 2007 Jun 8.

Experimental study that tests the immunological effects related to the use of Clenbuterol, demonstrating how this drug can determine a redistribution of white blood cells by increasing the number of neutrophils and monocytes to the detriment of eosinophils and lymphocytes.

CLENBUTEROL IN THE TREATMENT OF OSTRUCTIVE PATHOLOGIES OF AIRWAYS

Zhonghua Yi Xue Za Zhi (Taipei). 1991 Jan; 47 (1): 13-7.

Work that demonstrates how the use of Clenbuterol can represent a valid choice, both in terms of therapeutic efficacy and costs, for the long-term treatment of obstructive airway diseases, including reversible ones.

OVERDOSE OF CLENBUTEROL AND CARDIAC DISEASES

J Med Toxicol. 2007 Jun; 3 (2): 56-60.

Study demonstrating how the abuse of Clenbuterol, especially outside medical prescriptions and beyond the doses normally indicated, could be responsible, with a certain frequency of tachycardia and atrial fibrillation, sometimes with a severe and ominous outcome.

Method of use and dosage

MONORES ®

Clenbuterol 10-20 mcg tablet;

Syrup from 0.1 - 0.4 mg of Clenbuterol per 100 ml of product.

The definition of the therapeutic scheme is up to the doctor after having carefully evaluated the patient's general health and the severity of his clinical picture.

Dosages, intake times and pharmaceutical format therefore vary considerably from patient to patient based on their needs.

Generally in adults with asthma or asthma-like bronchopathies, the maximum recommended dose is 20 mcg twice a day, but taking care to identify the minimum dose necessary to guarantee the therapeutic effect during the maintenance phase.

Warnings MONORES ® - Clenbuterol

Therapy with MONORES ® must be defined and supervised by a specialist doctor in the treatment of respiratory diseases.

Given the biological activity of Clenbuterol, the use of this drug should be carried out with particular caution in patients suffering from cardiovascular diseases, glaucoma, hyperthyroidism, pheochromocytoma, diabetes and prostatic hypertrophy, potentially more susceptible to the side effects of therapy.

The need to increase the doses of the drug, to maintain the same therapeutic effect, could be an indication of an aggravation of the clinical conditions of the disease, such as to require further medical supervision and the possible need to modify the therapy in progress.

MONORES ® contains lactose among its excipients, therefore it is not indicated in patients with galactose intolerance, lactase enzyme deficiency and glucose-galactose malabsorption syndrome.

The use of MONORES ®, outside the medical prescriptions for which it is indicated, is prohibited in and out of the race.

It is recommended to keep the medicine out of the reach of children.

PREGNANCY AND BREASTFEEDING

The use of MONORES ® during pregnancy could be justified by inevitable clinical needs and should in any case take place under the careful supervision of your doctor.

However, it is important to consider the ability of Clenbuterol to inhibit uterine contractions and to concentrate in pharmacologically active doses in breast milk before using it during pregnancy and in the subsequent breastfeeding period.

Interactions

Patients taking MONORES ® should avoid the simultaneous intake of non-selective Beta 2 agonists and beta blockers, as well as diuretics, steroids and xanthine derivatives, potentially responsible for hypokalemia.

Contraindications MONORES ® - Clenbuterol

The use of MONORES ® is contraindicated in patients with hypersensitivity to the active substance or to one of its excipients, in patients suffering from severe cardiopathies, glaucoma, prostatic hypertrophy and urinary retention syndrome or intestinal obstruction:

Undesirable effects - Side effects

Therapy with MONORES ® could expose the patient to the risk of hyperglycaemia, hypokalemia, nervousness and restlessness, dizziness, headache and tremor, myalgia, muscle spasm, arrhythmia, palpitations, tachycardia and paradoxical bronchospasm.

Although the onset of symptoms linked to hypersensitivity to the active ingredient has also been rarely documented.